Revealing Key LncRNAs in Cytogenetically Normal Acute Myeloid Leukemia by Reconstruction of the LncRNA–miRNA–mRNA Network Based on the Competitive Endogenous RNA Theory

Tao Sun

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Lin Dong

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Yan Guo

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Hai Zhao

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Manzhi Wang (✉ jessicazhizhi@163.com.cn)

The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Research Article

Keywords: CN-AML, ceRNA, lncRNA, functional analysis, GABPB1-AS1

Posted Date: November 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1015372/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Cytogenetically normal acute myeloid leukemia(CN-AML) is a heterogeneous disease with different prognosis.Researches on prognostic indicators and therapy targets of CN-AML are still ongoing.Instead of protein-coding genes,more and more researches were focused on the non-coding RNAs especially long non-coding RNAs(lncRNAs) which may play an important role in the development and prognosis of AML.Although a large number of lncRNAs had been found, our knowledge of their function and pathological significance is still in its infancy.The purpose of this research is to identify the key lncRNAs and explore their function in CN-AML by reconstructing the lncRNA-miRNA-mRNA network based on the competitive endogenous RNA(ceRNA) theory.

Results

We reconstructed a global triple network based on the ceRNA theory using the data from National Center for Biotechnology Information Gene Expression Omnibus and published literature. According to the topological algorithm,we identified the key lncRNAs which had both the higher node degrees and the higher number of lncRNA-miRNA and miRNA-mRNA pairs in the ceRNA network. Meanwhile, Gene Ontology (GO) and pathway analysis were performed using databases such as DAVID,KOBAS and Cytoscape plug-in ClueGO respectively.The lncRNA-miRNA-mRNA network was composed of 90 lncRNAs,33mRNAs,26 miRNAs and 259 edges in the lncRNA upregulated group,and 18 lncRNAs,11 mRNAs,6 miRNAs and 45 edges in the lncRNA downregulated group.The functional assay showed that 53 pathways and 108 GO terms were enriched. Three lncRNAs(XIST,GABPB1-AS1,TUG1)could possibly be selected as key lncRNAs wihch may play an important role in the development of CN-AML.Particularly,GABPB1-AS1 was highly expressed in CN-AML by both bioinformatics analysis and experimental verification in AML cell line(THP-1) by quantitative real-time polymerase chain reaction.In addition, GABPB1-AS1 was also negatively correlated with overall survival of AML patients.

Conclusion

The lncRNA-miRNA-mRNA network revealed key lncRNAs and their functions in CN-AML.Particularly,lncRNA GABPB1-AS1 was firstly proposed in AML.We believe that GABPB1-AS1 is expected to become a candidate diagnostic biomarker or potential therapeutic target.

Background

Cytogenetically normal acute myeloid leukemia (CN-AML), a most common AML type,is characterized by the absence of microscopically detectable chromosome abnormalities.This is a heterogeneous disease with different prognosis.With the advent of high-throughput technologies,some prognostic gene

expression signatures have been proposed in CN-AML. For example, patients with FLT3-ITD mutation always had a bad prognosis[1], while NPM1 or CEBPA mutations indicated a good prognosis[2]. However, the vast majority of transcripts that were detected by high-throughput technologies do not appear to be protein-coding genes. Recently, accumulating evidence has suggested that rather than being transcriptional noise, many non-coding RNAs, especially the long non-coding RNAs (lncRNAs), served as master regulators that affect the expression levels of dozens or even hundreds of target genes[3], and may play an important role in pathogenesis of AML[4]. For example, lncRNA NEAT1 repressed the expression of miR-23a-3p and therefore modulated cell proliferation and apoptosis in AML by regulating SMC1A [5]. Furthermore, Garzon et al built a prognostic lncRNA score system for older patients (>60 years) with cytogenetically normal AML[6]. But the functional mechanisms of lncRNAs in CN-AML were complicated and unclear.

Noteworthy, competing endogenous RNA (ceRNA) network is a promising module to facilitate lncRNAs function in complex pathologic conditions. CeRNA network is a complex post-transcriptional regulatory network using miRNA response elements (MREs) to compete for the binding of miRNAs thereby implementing mutual control between mRNAs, lncRNAs and miRNA[7].

In summary, in order to explore the detailed pathogenesis of lncRNAs in AML, we reconstructed a global triple network in CN-AML compared with healthy controls using the data from National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) based on the ceRNA theory.

Results

Differentially expressed lncRNA, miRNA, and mRNA in CN-AML

A total of 127 mRNAs, 3380 lncRNAs, and 82 miRNAs were found to be differentially expressed in CN-AML group compared with normal controls ($|\log_2 \text{fold change}| > 1$ and $\text{adj. P value} < 0.05$ as the standards), of which 76 mRNAs (59.84%), 1751 lncRNAs (51.80%) and 19 miRNAs (23.17%) were upregulated while others were downregulated. Volcano plots, visually demonstrating the distribution of RNAs, were shown in Figure 1.

Reconstruction of the lncRNA–miRNA–mRNA network

To speculate on the functions of lncRNAs acting as miRNA targets, a network among lncRNAs, miRNAs, and mRNAs was reconstructed and then visualized. As shown in Figure 2, there were 90 lncRNAs, 33 mRNAs, 26 miRNAs and 259 edges in the lncRNA upregulated group, and 18 lncRNAs, 11 mRNAs, 6 miRNAs and 45 edges in the lncRNA downregulated group.

Topological analysis of the CN-AML related lncRNA–miRNA–mRNA network

It is well known that hub nodes play critical roles in biological networks. Therefore, we calculated all node degrees of the lncRNA– miRNA–mRNA network. According to the previous study by Han et al.[8]in which they defined a hub as a node degree exceeding 5,we found that 42 nodes could be chosen as hub nodes, including 10 lncRNAs, 31 miRNAs, and 1 mRNA(CDK6). Moreover, the number of the first relationship pairs of lncRNA–miRNA and the secondary relationship pairs of miRNA–mRNA were calculated. The results were shown in Table 1. Interestingly, we found that three lncRNAs (XIST,GABPB1-AS1,TUG1)not only had higher node degrees, but also had a higher number of lncRNA–miRNA and miRNA–mRNA pairs. This suggested that the three lncRNAs may play crucial roles in the development of CN-AML, which could be selected as the key lncRNAs.

Table 1
The topological algorithm of differentially expressed lncRNAs (Top10)

Number	Gene name	Node degree	lnc-miRNA pairs	mi-mRNA pairs	Total
1	XIST	20	20	38	58
2	GABPB1-AS1	10	10	13	23
3	TUG1	10	10	23	33
4	MIRLET7BHG	7	7	11	18
5	AC092127.1	6	6	12	18
6	SNHG1	6	6	9	15
7	NEAT1	5	5	11	16
8	SNHG3	5	5	9	14
9	H19	5	5	9	14
10	AC074117.1	5	5	9	14

Functional annotation of the lncRNA–miRNA–mRNA network

To understand the biological processes and pathways of DEmRNAs in the lncRNA–miRNA–mRNA network, we conducted the KEGG and GO enrichment analysis.

The KEGG results elucidated the potential biological functions(p-value < 0.05), a total of 53 significantly enriched pathways were obtained. Among these pathways, ‘PI3K-Akt signaling pathway’[9], ‘Ras signaling pathway’[10], ‘MAPK signaling pathway’[11], ‘FoxO signaling pathway’[12], were linked with the progression of AML. Additionally, some other pathways such as ‘Pathways in cancer’[13], ‘ErbB signaling

pathway'[14]were also tumor related pathways.Genes RUNX1,FLT3,KIT,FASLG,AKT3,MAPK8,GADD45A and PIK3R1 were enriched in greater than or equal to three pathway terms. The mentioned pathways were showed in Figure 3.

The DEmRNAs were classified into three functional groups: molecular function group, biological process group, and cellular component group. As shown in Figure 4, in the biological process group, DEmRNAs mainly enriched in G1/S transition of mitotic cell cycle, cell cycle arrest and protein phosphorylation.In the molecular function group, DEmRNAs mainly enriched in protein binding, ATP binding and protein kinase activity.In the cellular component group, DEmRNAs mainly enriched in nucleus,nucleoplasm and cytosol.

Reconstruction of the key lncRNA–miRNA–mRNA sub-networks

The key three lncRNAs(XIST,GABPB1-AS1,TUG1) and their linked miRNAs/mRNAs were extracted and used to reconstruct the new subnetworks as follows(Figure 5).Pathway analysis showed that LncRNA XIST related mRNA were significantly enriched in 16 pathway terms including 'PI3K-Akt signaling pathway','FoxO signaling pathway', 'p53 signaling pathway'[15] and 'Ras signaling pathway', all of which had been shown to play important roles in AML.LncRNA GABPB1-AS1 related mRNA were significantly enriched in 6 pathway terms including 'PI3K-Akt signaling pathway' and 'Pathways in cancer'pathway terms.LncRNA TUG1 related mRNA were significantly enriched in 12 pathway terms including 'PI3K-Akt signaling pathway','FoxO signaling pathway',and 'Ras signaling pathway',all of which had been shown to play important roles in AML.

Survival analysis of the key RNAs

We conducted the survival analysis of the key lncRNAs(showing in Table 1) and mRNAs(showing in Figure 3b) involved in the lncRNA–miRNA–mRNA network by Kaplan–Meier curve with P value<0.05.Only three lncRNAs(GABPB1-AS1,SNHG3,SNHG1)and two mRNA(FLT3,AKT3) significantly related to overall survival(OS) of AML patients(Figure 6).

The expression of GABPB1-AS1 in AML by quantitative real-time polymerase chain reaction(qRT-PCR)

To validate the above bioinformatics analysis, we used qRT-PCR to detect lncRNA GABPB1-AS1 expression in AML cell line(THP-1). GABPB1-AS1 which belonged to the core of the lncRNA–miRNA–mRNA network was significantly high expressed in THP-1 cells compared with HS-5 cells(control cell line) (p<0.01)(Figure 7).

Discussion

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. According to the WHO classification, patients with recurring cytogenetic abnormalities, such as t(8,21), inv(16)(p13q22) or t(15,17) often had a better prognosis [16]. But for those with normal karyotype, there is another story. Actually, CN-AML is a heterogeneous disease. Although with the advent of high-throughput sequencing and other methods, many genetic changes (such as mutations of gene FLT3, NPM1) which were closely related to the prognosis of CN-AML have been discovered, but the pathogenesis and prognostic markers of CN-AML were not yet fully understood. In recent years, more and more studies have focused on the epigenetic regulation of AML. Non-coding RNA (such as lncRNA or miRNA) is an important part of the epigenetic regulation. Recent studies have shown that lncRNAs are closely related to tumor cell proliferation, invasion, metastasis, apoptosis and tumor angiogenesis [17]. However, the specific regulatory mechanism of lncRNAs in CN-AML is still unclear. Since lncRNAs can regulate miRNAs abundance by binding and sequestering them which were known as “miRNA sponges”, lncRNAs can regulate the expression of target mRNAs [18]. Thus, it has been shown that an efficient way to infer the potential function of lncRNAs is by studying their relationship with miRNAs and/or mRNAs, whose functions have been annotated. Therefore, this suggested that we can use the ceRNA network to explore the specific functional roles and prognostic significance of lncRNAs in CN-AML.

In this study, we conducted the difference analysis between CN-AML patients and normal controls to find differentially expressed RNAs by GEO data sets (GSE142699, GSE142698 and GSE103828) and document retrieval. Then the target lncRNAs and mRNAs of miRNAs were searched through the online databases. Afterwards, we took the intersection between the target RNAs with the above-mentioned differentially expressed RNAs to obtain DElncRNA–DEmiRNA and DEmiRNA–DEmRNA pairs, in which the expression of DEmiRNAs were negatively correlated with DElncRNA and DEmRNA. Finally, a three-level network diagram of lncRNA–miRNA–mRNA was constructed.

We performed KEGG and GO analysis on the DEmRNAs in the lncRNA–miRNA–mRNA network. The pathway analysis showed that 29 pathways were significantly enriched (P-value < 0.05). Pathways ‘PI3K–Akt signaling pathway’, ‘MAPK signaling pathway’ and ‘Ras signaling pathway’, which have been shown to play important roles in AML, were involved. Furthermore, 108 GO terms were significantly enriched with P-value < 0.05. These significant GO terms involved G1/S transition of mitotic cell cycle, cell cycle arrest and protein phosphorylation for the biological process group; protein binding, ATP binding and protein kinase activity for the molecular function group; and nucleus, nucleoplasm and cytosol for the cellular component group.

In order to find the key lncRNAs, which can be used as potential novel biomarkers for clinical diagnosis and treatment targets of CN-AML, the hub nodes and the number of relationship pairs were used. In this study, three lncRNAs (XIST–GABPB1–AS1–TUG1) were observed to be topological key nodes whose node degrees and the number of lncRNA–miRNA and miRNA–mRNA pairs were significantly higher compared to other lncRNAs. This indicated that these lncRNAs had profound implications for AML, which can be considered as key lncRNAs.

LncRNA XIST

The XIST locus produces a 17–20 kb RNA that coats the X chromosome in cis, and plays an essential role in X chromosome inactivation (XCI)[19]. Much previous work has focused on the role of XIST in initiating X-inactivation in the early developing embryo. However, XIST has been reported to function as an oncogene or a tumor suppressor in different human malignancies, which is implicated in many aspects of carcinogenesis including tumor apoptosis, cell cycle, initiation, invasion, metastasis, stemness, autophagy and drug resistance[20]. For example, XIST was highly expressed in breast cancer and was closely associated with a poor prognosis and the resistance to chemotherapy[21]. Down-regulation of XIST has been reported to reduce chemoresistance in non-small cell lung cancer cells by inhibiting autophagy [22]. In AML, XIST was found to be up-regulated in patients' bone marrow cells. In addition, silencing of XIST could repress AML bone marrow cell proliferation while enhancing cell apoptosis and adriamycin sensitivity[23].

In this study, lncRNA XIST was highly expressed in CN-AML and had the highest node degrees and the highest number of lncRNA–miRNA and miRNA–mRNA pairs in the ceRNA network among all the lncRNAs. This means XIST may play an important role in CN-AML which is consistent with previous findings mentioned above. The pathway analysis of key lncRNA XIST–miRNA–mRNA sub-network showed that 16 pathways were significantly enriched. Pathways 'PI3K-Akt signaling pathway', 'FoxO signaling pathway', 'p53 signaling pathway' and 'Ras signaling pathway', which had been shown to play important roles in AML, were involved.

LncRNA GABPB1-AS1

LncRNA GABPB1 binding protein transcription factor subunit beta-1 antisense RNA 1 (GABPB1-AS1) is the antisense RNA of GABPB1 mRNA, which is located in the cytoplasm and has a total length of 4139 nt[24]. GABPB1-AS1 was identified for the first time in human-induced pluripotent stem cells (hiPSCs). The expression level of GABPB1-AS1 is increased in hiPSCs under the chemical stresses (cadmium, hydrogen peroxide, and cycloheximide)[25]. LncRNA GABPB1-AS1 also played a role in several cancers. But the results were contradictory. As a tumor suppressor gene, Qi et al found that GABPB1-AS1 inhibited the antioxidant ability of hepatocellular carcinoma cancer cells and cell proliferation by inhibiting the expression of GABPB1 and peroxiredoxin 5 (PRDX5)[26]. In addition, GABPB1-AS1 inhibited clear cell renal cell carcinoma growth and played a tumor suppressor role through an miR-1246/PCK1 axis[27]. As a tumor activator gene, GABPB1-AS1 can bind to miR-519e-5p and destroyed its tumor suppressive function in cervical cancer pathogenesis[28]. Furthermore, findings suggested that the decrease in GABPB1-AS1 expression associated with decreased breast cancer risk[29]. Alkhateeb et al also revealed that the aberrant expression of GABPB1-AS1 can be used as a potential prostate cancer biomarker[30]. However, the role of GABPB1-AS1 in AML is still unclear.

In this study, for the first time, we came to a conclusion that lncRNA GABPB1-AS1 was highly expressed in CN-AML by both bioinformatics analysis and qRT-PCR verification in AML cell line (THP-1). The pathway analysis of key lncRNA GABPB1-AS1–miRNA–mRNA sub-network showed that 6 pathways were

significantly enriched and primarily involved 'PI3K-Akt signaling pathway' and 'Pathways in cancer' pathway terms. In addition, the survival analysis told us that patients with lower expression of GABPB1-AS1 had better prognosis. In conclusion, GABPB1-AS1 would like to be a potential prognostic marker and therapeutic target of AML.

LncRNA TUG1

LncRNA Taurine-Upregulated Gene1 (TUG1), located on chromosome 22q12, a critical oncogenic lncRNAs of human, has been proved to take part in hematological cancers. Interestingly, Some scholars demonstrated that TUG1 was highly expressed in tissues and cell lines of AML patients, and the high expression of TUG1 was also closely related to poor prognosis of AML[31]. TUG1 induced cell proliferation, and restrained cell apoptosis in AML by targeting aurora kinase A[32]. TUG1 facilitates the cell viability and metastasis by targeting miR-370-3p/MAPK1/ERK in AML[33]. In addition, TUG1 silencing decreased the IC50 of adriamycin, and promotes adriamycin-induced apoptosis in AML cells by miR-34a/EZH2 axis[34], providing a potential therapeutic target for AML.

In our study, LncRNA TUG1 was highly expressed in CN-AML and had the higher topological parameters in the ceRNA network. This means TUG1 may play an important role in CN-AML which was consistent with previous findings mentioned above. The pathway analysis of key lncRNA TUG1-miRNA-mRNA sub-network showed that 16 pathways were enriched. Pathways 'PI3K-Akt signaling pathway', 'FoxO signaling pathway', and 'Ras signaling pathway', which have been shown to play important roles in AML, were involved.

In summary, our research results constructed a lncRNA-miRNA-mRNA network associated with CN-AML, and provided novel lncRNAs (especially GABPB1-AS1) as potential diagnostic and prognostic biomarkers. The specific functional mechanism of these key lncRNAs in AML needs further experimental exploration.

Conclusion

Based on the ceRNA theory, we reconstructed a lncRNA-miRNA-mRNA network for CN-AML compared with normal controls for the first time. According to the topological algorithm, our study further found that three lncRNAs (XIST, GABPB1-AS1, TUG1) could possibly be selected as key lncRNAs which may play an important role in the development of CN-AML. Particularly, LncRNA GABPB1-AS1 was firstly proposed in AML. GABPB1-AS1 was highly expressed in CN-AML by both bioinformatics analysis and qRT-PCR verification in AML cell line (THP-1). In addition, it was also negatively correlated with OS of AML patients. So GABPB1-AS1 is expected to become a candidate diagnostic biomarker or potential therapeutic target. In addition, we conducted the functional analysis of the ceRNA network to advance our understanding of the pathogenesis of CN-AML from the perspective of lncRNAs. Further studies are needed to explore the biological functions and molecular mechanisms of these specific lncRNAs in CN-AML.

Methods

Raw data

GEO is a public functional genomics data repository supporting MIAME-compliant data submissions. Array- and sequence-based data were accepted.

In order to find the differentially expressed miRNAs, mRNAs and lncRNAs in CN-AML compared with normal controls, databases (GSE142699, GSE142698 and GSE103828) were downloaded respectively from NCBI GEO.

In addition, we also searched in PubMed [35] by keywords 'acute myeloid leukemia and lncRNA' to find lncRNAs which have been reported to have significantly differential expressions in CN-AML.

The RNA-seq data and clinical data are publicly available on open-access. Therefore, no further approval was required from the local ethics committee.

Screening differentially expressed lncRNAs, miRNAs and mRNAs

The 'edgeR' package [36] was utilized to identify the differentially expressed RNAs in CN-AML compared with normal controls, the downloaded data were calibrated, standardized and analyzed for differences to obtain differentially expressed lncRNA, miRNA, and mRNA molecules between the CN-AML group and control. The screening criteria of the three kinds of dysregulated RNAs were as follows: $\text{adj.p value} < 0.05$ and $|\log_2 \text{fold change}| > 1$.

For lncRNAs, differentially expressed lncRNAs also includes the ones obtained from the published literature.

Prediction of target lncRNAs and mRNAs of differentially expressed miRNAs

In this study, starbase website [37] was used to predict lncRNA-miRNA interactions. In addition, the online websites miRDB [38], miRTarBase [39], TargetScan [40] were used to predict target genes. In TargetScan, predicted targets are ranked according to the predicted efficacy of targeting as calculated using cumulative weighted context++ scores of the sites, and $\text{scores} < -0.1$ were selected. Genes that appear in at least two databases or more are regarded as target genes.

Reconstruction of the lncRNA-miRNA-mRNA network

To further improve the reliability of bioinformatics analysis, we obtained the portion of the target mRNAs or lncRNAs that overlapped with the differentially expressed mRNAs or lncRNAs in CN-AML compared with normal controls, and overlapping RNAs were further analyzed as differentially expressed

mRNAs(DEmRNAs) or differentially expressed lncRNAs(DElncRNAs). Finally, we established matched DElncRNA–DEmiRNA and DEmiRNA–DEmRNA pairs.

The lncRNA–miRNA–mRNA network was reconstructed based on ceRNA theory as follows: For a given co-expressed lncRNA– mRNA pair, both lncRNA and mRNA in this pair were targeted and co-expressed negatively with a certain common miRNA, and this lncRNA–miRNA–mRNA was identified as the co-expression competing triplet. The lncRNA–miRNA–mRNA network was reconstructed by assembling all co-expression competing triplets, which were identified above, and was visualized using Cytoscape software. Simultaneously, all node degrees of the lncRNA–miRNA–mRNA network were calculated.

Functional enrichment analysis

To assess functional enrichment, Gene Ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of mRNAs in the lncRNA–miRNA– mRNA network were performed using multiple online databases, including DAVID(Database for Annotation, Visualization, and Integration Discovery)[41] and KOBAS[42] with $p < 0.05$ as the cut-off criterion. Then the KEGG pathway interaction network was reconstructed using Cytoscape plug-in ClueGO.

Reconstruction of the key lncRNA–miRNA–mRNA sub-networks

Every lncRNA, its linked miRNAs and mRNAs in the global triple network were extracted and used to reconstruct the new subnetwork using Cytoscape software. Meanwhile, the number of the first relationship pairs of lncRNA–miRNA and the secondary relationship pairs of miRNA–mRNA were calculated. Using the node degree of lncRNAs, the number of the first relationship pairs of lncRNA–miRNA plus the secondary relationship pairs of miRNA–mRNA, the key lncRNAs were collected. For further analysis, we performed pathway annotations for each of the key lncRNAs by using their first mRNA neighbors in the key lncRNA–miRNA–mRNA sub-networks.

Survival analysis

To explore the relationship between prognosis and the key lncRNAs, miRNAs and mRNAs involved in the ceRNA network, Kaplan–Meier curve were carried out at a P value < 0.05 using the online websites GEPIA2(Gene Expression Profiling Interactive Analysis)[43] .

RNA extraction, reverse transcription(RT), and quantitative real-time polymerase chain reaction(qRT-PCR)

The total RNAs were extracted using TRIzol kits (Pufei,Shanghai,China) for qRT-PCR analyses.Reverse transcription was then conducted by applying the Promega RT reagent Kit(Promega M-MLV M1705,Madison,USA). qRT-PCR using SYBR Green Mix (TAKARA,Dalian,China) was carried out on Roche LightCycler 480II system in triplicate. Primers for GABPB1-AS1 and β -actin were synthesized by Genechem Co.,Ltd.(Shanghai, China). The mRNA expressions were normalized to β -actin.The expressing

levels of lncRNAs were defined based on the threshold cycle (Ct), and calculated using the $2^{-\Delta\Delta CT}$ method. The primers were as follows:

GABPB1-AS1 forward primer: CAACTAGGCAGACTGGGACG,

GABPB1-AS1 reverse primer: AGGTGGCAGTAATCCAAGCA,

β -actin forward primer: GCGTGACATTAAGGAGAAGC,

β -actin reverse primer: CCACGTCACACTTCATGATGG.

Statistical analysis

All data collected from three independent experiments are presented as mean $\pm$ standard deviation. Survival curves were plotted using the Kaplan–Meier method and the log-rank test. Student's t test for comparison between two groups were performed for statistical analysis using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). A p value of less than 0.05 was identified as having statistical significance.

Abbreviations

CN-AML (Cytogenetically normal acute myeloid leukemia), lncRNAs (long non-coding RNAs), ceRNA (competing endogenous RNA), MREs (miRNA response elements), NCBI GEO (National Center for Biotechnology Information Gene Expression Omnibus), DEmRNAs (differentially expressed mRNAs), DE miRNAs (differentially expressed miRNAs), DE lncRNAs (differentially expressed lncRNAs), RT (reverse transcription), qRT-PCR (quantitative real-time polymerase chain reaction), CT (cycle threshold), OS (overall survival).

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: The datasets generated and/or analysed during the current study are available in the NCBI GEO repository, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142699>,⁴⁴ <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142698>,⁴⁵ <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103828>.⁴⁶

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by the Cultivated National Natural Science Foundation Project of Shandong Qianfoshan Hospital under Grant [number QYPY2020NSFC0617] in analysis of data, verification in cell line and in writing the manuscript.

Authors' contributions: MZW and TS designed the work; TS, LD and YG collected data from the public datasets and literature; TS, MZW and HZ analyzed data; HZ, LD and YG performed qRT-PCR experiment in cell lines; TS drafted the work; MZW revised it. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

References

1. Antar AI, Otrrock ZK, Jabbour E, Mohty M, Bazarbachi A: **FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.** *Leukemia* 2020, **34**(3):682-696.
2. Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, et al: **CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.** *Haematologica* 2017, **102**(3):529-540.
3. Ye N, Rao S, Du T, Hu H, Liu Z, Shen Y, Xu Q: **Intergenic variants may predispose to major depression disorder through regulation of long non-coding RNA expression.** *Gene* 2017, **601**:21-26.
4. Junge A, Zandi R, Havgaard JH, Gorodkin J, Cowland JB: **Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.** *Gene* 2017, **615**:35-40.
5. Zhao C, Wang S, Zhao Y, Du F, Wang W, Lv P, Qi L: **Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia.** *J Cell Physiol* 2019, **234**(5):6161-6172.
6. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrozek K, Bucci D, Carroll AJ, Baer MR, et al: **Expression and prognostic impact of lncRNAs in acute myeloid leukemia.** *Proc Natl Acad Sci U S A* 2014, **111**(52):18679-18684.
7. Song X, Cao G, Jing L, Lin S, Wang X, Zhang J, Wang M, Liu W, Lv C: **Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis.** *J Cell Mol Med* 2014, **18**(6):991-1003.
8. Han JD, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV, Dupuy D, Walhout AJ, Cusick ME, Roth FP, Vidal M: **Evidence for dynamically organized modularity in the yeast protein-protein interaction network.** *Nature* 2004, **430**(6995):88-93.
9. Herschbein L, Liesveld JL: **Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.** *Blood Rev* 2018, **32**(3):235-248.
10. Liu X, Ye Q, Zhao XP, Zhang PB, Li S, Li RQ, Zhao XL: **RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.** *Clin Chim Acta* 2019, **489**:254-260.
11. Feng Y, Li L, Du Y, Peng X, Chen F: **E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2.** *J Cell Mol Med* 2020, **24**(3):2157-2168.
12. Jiang M, Chen Y, Deng L, Luo X, Wang L, Liu L: **Upregulation of SPAG6 in Myelodysplastic Syndrome: Knockdown Inhibits Cell Proliferation via AKT/FOXO Signaling Pathway.** *DNA Cell Biol* 2019,

13. Yang H, Zhang X, Cai XY, Wen DY, Ye ZH, Liang L, Zhang L, Wang HL, Chen G, Feng ZB: **From big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma.** *PeerJ* 2017, **5**:e3089.
14. Chang YH, Yu CH, Jou ST, Lin CY, Lin KH, Lu MY, Wu KH, Chang HH, Lin DT, Lin SW, et al: **Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.** *Sci Rep* 2021, **11**(1):769.
15. Li B, Hu J, He D, Chen Q, Liu S, Zhu X, Yu M: **PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.** *Technol Cancer Res Treat* 2020, **19**:1533033820942312.
16. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National Cancer Research Institute Adult Leukaemia Working G: **Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.** *Blood* 2010, **116**(3):354-365.
17. Zheng Q, Gu X, Yang Q, Chu Q, Dai Y, Chen Z: **DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression.** *Clin Chim Acta* 2021, **517**:1-8.
18. Ye S, Yang L, Zhao X, Song W, Wang W, Zheng S: **Bioinformatics method to predict two regulation mechanism: TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer.** *Cell Biochem Biophys* 2014, **70**(3):1849-1858.
19. Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N: **Requirement for Xist in X chromosome inactivation.** *Nature* 1996, **379**(6561):131-137.
20. Yang Z, Jiang X, Jiang X, Zhao H: **X-inactive-specific transcript: A long noncoding RNA with complex roles in human cancers.** *Gene* 2018, **679**:28-35.
21. Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC: **High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.** *Mol Cancer Ther* 2016, **15**(1):190-198.
22. Sun W, Zu Y, Fu X, Deng Y: **Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy.** *Oncol Rep* 2017, **38**(6):3347-3354.
23. Wang C, Li L, Li M, Wang W, Liu Y, Wang S: **Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression.** *Mol Med* 2020, **26**(1):114.
24. Tani H, Torimura M: **Identification of short-lived long non-coding RNAs as surrogate indicators for chemical stress response.** *Biochem Biophys Res Commun* 2013, **439**(4):547-551.
25. Tani H, Onuma Y, Ito Y, Torimura M: **Long non-coding RNAs as surrogate indicators for chemical stress responses in human-induced pluripotent stem cells.** *PLoS One* 2014, **9**(8):e106282.
26. Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C, Xu S: **LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells.** *Sci Rep* 2019,

9(1):16185.

27. Gao S, Zhang F, Sun H, Yang X: **LncRNA GA-Binding Protein Transcription Factor Subunit Beta-1 Antisense RNA 1 Inhibits Renal Carcinoma Growth Through an MiR-1246/Phosphoenolpyruvate Carboxykinase 1 Pathway.** *Onco Targets Ther* 2020, **13**:6827-6836.
28. Ou R, Lv M, Liu X, Lv J, Zhao J, Zhao Y, Li X, Li W, Zhao L, Li J, et al: **HPV16 E6 oncoprotein-induced upregulation of lncRNA GABPB1-AS1 facilitates cervical cancer progression by regulating miR-519e-5p/Notch2 axis.** *FASEB J* 2020, **34**(10):13211-13223.
29. Suvanto M, Beesley J, Blomqvist C, Chenevix-Trench G, Khan S, Nevanlinna H: **SNPs in lncRNA Regions and Breast Cancer Risk.** *Front Genet* 2020, **11**:550.
30. Alkhateeb A, Rezaeian I, Singireddy S, Cavallo-Medved D, Porter LA, Rueda L: **Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate Cancer.** *Cancer Inform* 2019, **18**:1176935119835522.
31. Qin J, Bao H, Li H: **Correlation of long non-coding RNA taurine-upregulated gene 1 with disease conditions and prognosis, as well as its effect on cell activities in acute myeloid leukemia.** *Cancer Biomark* 2018, **23**(4):569-577.
32. Wang X, Zhang L, Zhao F, Xu R, Jiang J, Zhang C, Liu H, Huang H: **Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.** *Ann Hematol* 2018, **97**(8):1375-1389.
33. Li G, Zheng P, Wang H, Ai Y, Mao X: **Long Non-Coding RNA TUG1 Modulates Proliferation, Migration, And Invasion Of Acute Myeloid Leukemia Cells Via Regulating miR-370-3p/MAPK1/ERK.** *Onco Targets Ther* 2019, **12**:10375-10388.
34. Li Q, Song W, Wang J: **TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.** *Biomed Pharmacother* 2019, **109**:1793-1801.
35. <https://pubmed.ncbi.nlm.nih.gov>. Accessed 1 May 2021.
36. Robinson MD, McCarthy DJ, Smyth GK: **edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.** *Bioinformatics* 2010, **26**(1):139-140.
37. Li JH, Liu S, Zhou H, Qu LH, Yang JH: **starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.** *Nucleic Acids Res* 2014, **42**(Database issue):D92-97. <http://starbase.sysu.edu.cn/>. Accessed 5 May 2021.
38. Wong N, Wang X: **miRDB: an online resource for microRNA target prediction and functional annotations.** *Nucleic Acids Res* 2015, **43**(Database issue):D146-152. <http://www.mirdb.org/>. Accessed 7 May 2021.
39. Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: **miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database.** *Nucleic Acids Res* 2016, **44**(D1):D239-247. <http://mirtarbase.mbc.nctu.edu.tw>. Accessed 9 May 2021.

40. Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ: **A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.** *Annu Rev Genet* 2015, **49**:213-242.
<http://www.targetscan.org>.Accessed 9 May 2021.
41. Huang da W, Sherman BT, Lempicki RA: **Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.** *Nat Protoc* 2009, **4**(1):44-57.
<http://david.abcc.ncifcrf.gov/>.Accessed 20 May 2021.
42. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, Wei L: **KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases.** *Nucleic Acids Res* 2011, **39**(Web Server issue):W316-322. <http://kobas.cbi.pku.edu.cn/>.Accessed 20 May 2021.
43. Tang Z, Kang B, Li C, Chen T, Zhang Z: **GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.** *Nucleic Acids Res* 2019, **47**(W1):W556-W560.<http://gepia2.cancer-pku.cn/>.Accessed 5 June 2021.
44. Esa E, Hashim AK, Zakaria Z, Hassan AN, Yusoff YM, Kamaluddin NR, Rahman AZ, Mohamed EH, Meng CK, Mohamed R, et al: **Co-expression of microrna and mrna in cytogenetically normal acute myeloid leukemia patients [miRNA].**2019. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142699>.
45. Esa E, Hashim AK, Zakaria Z, Hassan AN, Yusoff YM, Kamaluddin NR, Rahman AZ, Mohamed EH, Meng CK, Mohamed R, et al: **Co-expression of microrna and mrna in cytogenetically normal acute myeloid leukemia patients [mRNA].**2019.<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142698>.
46. Feng Y, Shen Y, Chen H, Wang X, Zhang R, Peng Y, Lei X, Liu T, Liu J, Gu L, et al. **Expression profile analysis of long non-coding RNA in acute myeloid leukemia by microarray and bioinformatics.**2018. <https://onlinelibrary.wiley.com/doi/10.1111/cas.13465>.

Figures

Figure 1

Volcano plots reflecting number, significance and reliability of differentially expressed RNAs in CN-AML compared with normal controls. The red dots indicate upregulation and blue dots indicate downregulation of mRNAs (A), miRNAs(B) and LncRNAs(C). The x-axis represents the value of $\log_2(\text{Fold Change})$ and the y-axis represents the value of $-\log_{10}(\text{p-value})$.

LncRNA upregulated group(A)

LncRNA downregulated group(B)

Figure 2

The view of the LncRNA–miRNA–mRNA network in CN-AML. The square represents LncRNAs, the rhombus represents mRNAs, and the circle represents miRNAs. There were 90 LncRNAs, 33 mRNAs, 26 miRNAs and 259 edges in the LncRNA upregulated group(A), and 18 LncRNAs, 11 mRNAs, 6 miRNAs and 45 edges in the LncRNA downregulated group(B).

Figure 3

KEGG pathway analysis of DE mRNAs in the lncRNA–miRNA–mRNA network. (A) The top 20 significantly enriched pathway terms by KOBAS. (B) The KEGG pathway interactions by Cytoscape plug-in ClueGO. Genes RUNX1, FLT3, KIT, FASLG, AKT3, MAPK8, GADD45A and PIK3R1 were enriched in pathways greater than two terms by Cytoscape plug-in ClueGO.

Figure 4

Gene Ontology analysis and significantly enriched GO terms of DEmRNAs in the lncRNA-miRNA-mRNA network.(A)Significantly Enriched GO Terms of DEmRNAs in the lncRNA-miRNA-mRNA network based on their functions.(B)GO analysis classified DEmRNAs in the lncRNA-miRNA-mRNA network into 3 groups(i.e.,molecular function,biological process and cellular component).

Figure 6

Kaplan–Meier curves of three lncRNAs(GABPB1-AS1(A),SNHG3(B),SNHG1(C))and two mRNA(FLT3(D),AKT3(E)) in AML with logrank $p \leq 0.05$.

Figure 7

Comparing differences in the expression levels of GABPB1-AS1 between THP-1 cells and normal HS-5 cells. * $p < 0.01$